International Journal of Cancer最新文献_第5页

Decoding the crossroads of aging and cancer through single-cell analysis: Implications for precision oncology. 通过单细胞分析解码衰老和癌症的十字路口：对精确肿瘤学的影响。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-23 DOI: 10.1002/ijc.35456

Dengxiong Li, Qingxin Yu, Fanglin Shao, Jie Wang, Ruicheng Wu, Yiqing Guo, Koo Han Yoo, Zhipeng Wang, Wuran Wei, Dechao Feng

{"title":"Decoding the crossroads of aging and cancer through single-cell analysis: Implications for precision oncology.","authors":"Dengxiong Li, Qingxin Yu, Fanglin Shao, Jie Wang, Ruicheng Wu, Yiqing Guo, Koo Han Yoo, Zhipeng Wang, Wuran Wei, Dechao Feng","doi":"10.1002/ijc.35456","DOIUrl":"https://doi.org/10.1002/ijc.35456","url":null,"abstract":"Single-cell analysis is a transformative approach to understanding cellular heterogeneity in aging and cancer, interconnected processes driven by mechanisms like senescence and immune modulation. This review explores how aging influences cancer initiation, progression, and treatment resistance within the tumor microenvironment (TME). By examining recent studies using single-cell technologies, we reveal the nuanced roles of aging in tumorigenesis, immune interactions, and therapeutic outcomes. Aging is closely tied to cancer progression, with senescent cells demonstrating heightened proliferative, invasive, and metastatic capabilities. Emerging senolytic therapies targeting aging-related pathways hold promise for enhancing treatment efficacy. Advanced tools such as spatial transcriptomics, molecular probes, and artificial intelligence further refine our understanding of aging-related heterogeneity in the TME. By integrating single-cell analysis with these technologies, future research can clarify the intricate interactions between aging and cancer, advancing precision oncology and improving outcomes for aging cancer patients.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carboplatin-gemcitabine for refractory high-grade meningiomas: A study from the French national OMEGA consortium. 卡铂-吉西他滨治疗难治性高级别脑膜瘤：一项来自法国国家OMEGA联盟的研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-21 DOI: 10.1002/ijc.35453

Mathieu Larroquette, Charlotte Bronnimann, Morgan Ollivier, Thomas Daubon, Paul Lesueur, Carole Ramirez, Ahmed Idbaih, Michel Kalamarides, Matthieu Peyre, Julien Engelhardt

{"title":"Carboplatin-gemcitabine for refractory high-grade meningiomas: A study from the French national OMEGA consortium.","authors":"Mathieu Larroquette, Charlotte Bronnimann, Morgan Ollivier, Thomas Daubon, Paul Lesueur, Carole Ramirez, Ahmed Idbaih, Michel Kalamarides, Matthieu Peyre, Julien Engelhardt","doi":"10.1002/ijc.35453","DOIUrl":"https://doi.org/10.1002/ijc.35453","url":null,"abstract":"High-grade meningiomas are rare tumours that often relapse and are difficult to treat, and no clearly recommended systemic treatment is available. In this study, we assessed the efficacy of carboplatin-gemcitabine as a systemic chemotherapy regimen administered to patients with high-grade recurrent meningiomas after observing incidental tumour shrinkage in one patient. Carboplatin-gemcitabine was offered on a compassionate basis to French patients with high-grade recurrent meningioma within the framework of the French Réunion d'orientation thérapeutique des méningiomes de haut grade (OMEGA) multidisciplinary board, which discusses all meningioma cases nationwide that are not amenable to standard treatment (surgery or radiotherapy). We retrospectively analysed the efficacy of this treatment in French patients from 2019 to 2023. We evaluated the three-dimensional volumetric kinetics of the tumour, progression-free survival (PFS), and safety. Carboplatin-gemcitabine slowed tumour growth for several months in some heavily pretreated patients despite the failure of previous systemic therapies. The 6-month PFS rate for the cohort of six patients was 50% (95% confidence interval, [22.5-100%]). Safety was characterised by asthenia and manageable haematological toxicity. Our results provide encouraging data on the efficacy of carboplatin-gemcitabine for meningiomas and should be validated in a prospective trial. Despite the small number of patients, our study included all French patients treated for a 4-year period and should be considered alongside other previously published studies, which also included few patients due to the rarity of the disease. Our findings highlight the importance of national networks for managing these patients and the need for multicentre trials.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score-matched analysis. 晚期肺腺癌患者一线免疫化疗中免疫治疗时间对预后的影响：倾向评分匹配分析

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-21 DOI: 10.1002/ijc.35447

Yanxin Sun, Zhenzhen Deng, Haifeng Sun, Xiaojuan Wei, Leirong Wang, Shuyun Wang, Aiqin Gao, Yuping Sun, Juan Li

{"title":"Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score-matched analysis.","authors":"Yanxin Sun, Zhenzhen Deng, Haifeng Sun, Xiaojuan Wei, Leirong Wang, Shuyun Wang, Aiqin Gao, Yuping Sun, Juan Li","doi":"10.1002/ijc.35447","DOIUrl":"https://doi.org/10.1002/ijc.35447","url":null,"abstract":"Immunochemotherapy combinations have been the standard first-line therapy for advanced lung adenocarcinoma (LUAD) without driver mutations, wherein concurrent chemotherapy and immunotherapy are conventionally anchored in the established dosing regimen. A few studies have suggested that the timing of immunotherapy in combinations may have a significant impact on the efficacy. However, this issue has not been addressed in an advanced LUAD cohort. We aimed to investigate the prognostic significance of the timing of immunotherapy in first-line immunochemotherapy combinations for patients with advanced LUAD. We retrospectively analyzed 508 patients with advanced LUAD without driver mutations who received immunochemotherapy as initial systemic treatment. The patients were divided into two groups-the induction and non-induction groups-with induction defined as receiving chemotherapy alone before concurrent immunochemotherapy. The bias between different groups was minimized using propensity score matching (PSM). We found both the PFS and OS of the patients in the induction group were significantly longer than those in the non-induction group before (PFS: p < 0.0001, OS: p < 0.0001) and after PSM (PFS: p = 0.0045, OS: p = 0.00073). After adjusting for confounders, induction chemotherapy was still a significant favorable factor for both PFS (p = 0.001) and OS (p = 0.001). In subsequent analyses, we found that both ≥2-cycles induction (PFS: p = 0.000, OS: p = 0.000) and 1-cycle induction (PFS: p = 0.013, OS: p = 0.002) were superior to non-induction and these differences were still significant after PSM. Our findings highlight the notable benefits of induction chemotherapy for patients with advanced LUAD treated with first-line immunochemotherapy combinations.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted plasma lipidomic profiles associated with colorectal cancer risk and effect modifications by common risk factors and particulate matter exposure. 与结直肠癌风险相关的靶向血浆脂质组学特征以及常见危险因素和颗粒物暴露的影响改变

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-21 DOI: 10.1002/ijc.35449

Yuhan Zhou, Ming Fu, Xin Guan, Chenming Wang, Yang Xiao, Shiru Hong, Hui Zhao, Yuxi Wang, Chenliang Liu, Yingqian You, Guorong Zhong, Tianhao Wu, Shengli Chen, Yichi Zhang, Huan Guo

{"title":"Targeted plasma lipidomic profiles associated with colorectal cancer risk and effect modifications by common risk factors and particulate matter exposure.","authors":"Yuhan Zhou, Ming Fu, Xin Guan, Chenming Wang, Yang Xiao, Shiru Hong, Hui Zhao, Yuxi Wang, Chenliang Liu, Yingqian You, Guorong Zhong, Tianhao Wu, Shengli Chen, Yichi Zhang, Huan Guo","doi":"10.1002/ijc.35449","DOIUrl":"https://doi.org/10.1002/ijc.35449","url":null,"abstract":"The role of specific lipids in colorectal cancer (CRC) incidence remains unclear. We aimed to evaluate associations of plasma lipids with CRC risk and the modification effects of common risk factors and ambient particulate matter (PM) exposure. We conducted a nested case-control study within the Dongfeng-Tongji cohort, including 218 cases and 436 matched controls. Plasma levels of 155 lipids were determined by UPLC-MS/MS. The conditional logistic regression and LASSO regression identified nine lipids as potential CRC risk biomarkers. Specifically, triacylglycerol (TAG) 56:7 [20:4], cholesterol ester (CE) 20:2 (1), CE 22:5, lysophosphatidylethanolamine (LPE) 18:2, and sphingomyelin (SM) 32:2 were associated with decreased CRC risk (adjusted ORs per SD: 0.05-0.68), while LPE 18:0, diglycerol (DAG) 16:1/17:1, SM 38:1, and SM 34:0 were associated with increased CRC risk (ORs per SD: 1.60-6.19). Compared to the traditional factors, these lipids exerted improvement of 35.4% in area under the curve (AUC) discriminations for CRC (AUC = 0.972 vs. 0.618). Notably, the associations between specific lipids and CRC risk were modified by BMI (TAG 56:7 [20:4]), smoking (LPE 18:0, DAG 16:1/17:1), alcohol consumption (SM 32:2), healthy diet (TAG 56:7 [20:4]), and PM exposure (TAG 56:7 [20:4], DAG 16:1/17:1, SM 38:1, LPE 18:2) (all Pinteraction <0.05). Our study identified 9 plasma lipids with significant associations with CRC risk and underscored the effect modifications of common risk factors and PM exposure on these associations. These findings provide new insights into the links between specific lipids and CRC development.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients. Lynch-like综合征患者的综合遗传学和表观遗传学特征。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-21 DOI: 10.1002/ijc.35451

Francesca Pirini, Luciano Calzari, Gianluca Tedaldi, Michela Tebaldi, Valentina Zampiga, Ilaria Cangini, Rita Danesi, Mila Ravegnani, Valentina Arcangeli, Alessandro Passardi, Elisabetta Petracci, Sara Bravaccini, Giorgia Marisi, Alessandra Viel, Daniela Barana, Monica Pedroni, Luca Roncucci, Daniele Calistri, Davide Gentilini

{"title":"Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients.","authors":"Francesca Pirini, Luciano Calzari, Gianluca Tedaldi, Michela Tebaldi, Valentina Zampiga, Ilaria Cangini, Rita Danesi, Mila Ravegnani, Valentina Arcangeli, Alessandro Passardi, Elisabetta Petracci, Sara Bravaccini, Giorgia Marisi, Alessandra Viel, Daniela Barana, Monica Pedroni, Luca Roncucci, Daniele Calistri, Davide Gentilini","doi":"10.1002/ijc.35451","DOIUrl":"https://doi.org/10.1002/ijc.35451","url":null,"abstract":"Lynch-like syndrome (LLS) presents very similar clinicopathological characteristics to Lynch syndrome (LS) but the mechanism for cancer predisposition remains unknown. The present study aims to investigate the causal mechanism of LLS by a comprehensive genetic and epigenetic approach. Thirty-two LLS and 34 LS patients with colorectal cancer (CRC) fitting the Amsterdam and Bethesda criteria were included, along with 29 CRC sporadic patients, and analyzed for the presence of pathogenic variants in 94 genes associated with hereditary tumors. The cohorts were also characterized for the methylation profile and examined through a sample group analysis and a Stochastic Epigenetic Mutations (SEMs) analysis in comparison with 29 age-matched healthy controls. The multigene panel analysis revealed the presence of pathogenic variants in non-mismatch repair (MMR) genes and three variants classified as pathogenic/likely pathogenic possibly predisposing to LLS. The epigenetic analysis showed epivariations targeting genes associated with LS or DNA repair, most of them associated with the Fanconi Anemia pathway, which could explain the susceptibility to cancer. Our results highlight the need for using extended genetic and epigenetic analyses to understand the causal mechanism of LLS.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histologically verified penile lichen sclerosus-Incidence in Denmark over 26 years and long-term risk of penile and non-penile cancer. 组织学证实的阴茎地衣硬化：丹麦26年以上阴茎癌和非阴茎癌的发病率和长期风险。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-18 DOI: 10.1002/ijc.35454

Marianne Gardar Stærk, Emma L Kaderly Rasmussen, Charlotte Gerd Hannibal, Rasmus Hertzum-Larsen, Louise Baandrup, Susanne K Kjær

{"title":"Histologically verified penile lichen sclerosus-Incidence in Denmark over 26 years and long-term risk of penile and non-penile cancer.","authors":"Marianne Gardar Stærk, Emma L Kaderly Rasmussen, Charlotte Gerd Hannibal, Rasmus Hertzum-Larsen, Louise Baandrup, Susanne K Kjær","doi":"10.1002/ijc.35454","DOIUrl":"https://doi.org/10.1002/ijc.35454","url":null,"abstract":"Lichen sclerosus (LSc) is a chronic inflammatory disease affecting the anogenital area and having malignant potential. Population-based data on the incidence of LSc in men and associated cancer risk are sparse. In the Danish Pathology Register, we identified all men with histologically verified penile LSc 1997-2022 and calculated incidence rates. Through linkage with the Danish Cancer Registry, standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were computed as relative risk estimates of penile squamous cell carcinoma (SCC) and non-penile cancer in men with penile LSc (1978-2019) compared with background population rates. During the study period, the age-standardized incidence rate of penile LSc more than doubled, being 17.9 per 100,000 person-years in the most recent time (2021-2022). The age-specific incidence increased with age and was highest in ages 70-79 years (29.2 per 100,000 person-years). Compared with the general population, men with penile LSc had an increased rate of penile SCC (SIR = 15.5, 95% CI: 12.0-19.5), which increased with follow-up length and younger age at LSc diagnosis. Rates of non-penile cancers were mostly close to unity except for lung cancer (SIR = 0.6, 95% CI: 0.5-0.7). This nationwide study showed an increased incidence of histologically verified penile LSc over the past 26 years. Importantly, men with penile LSc had nearly 16 times higher rate of penile SCC compared with the general population. There was no strong association with the non-penile cancers, except for a lower rate of lung cancer, suggesting that the malignant potential of LSc is caused by local factors rather than a general cancer predisposition.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status. 癌症幸存者中第二原发肺癌的风险按第一原发癌部位和肺癌筛查资格分层。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-18 DOI: 10.1002/ijc.35452

Sara Nofal, Edwin J Ostrin, Jianjun Zhang, Jia Wu, Paul Scheet, Mara B Antonoff, John V Heymach, Iakovos Toumazis

{"title":"Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.","authors":"Sara Nofal, Edwin J Ostrin, Jianjun Zhang, Jia Wu, Paul Scheet, Mara B Antonoff, John V Heymach, Iakovos Toumazis","doi":"10.1002/ijc.35452","DOIUrl":"https://doi.org/10.1002/ijc.35452","url":null,"abstract":"Personal history of cancer is an independent risk factor for developing lung cancer. However, it is not considered in the current US lung cancer screening (LCS) guidelines. In this study, we assessed the risk of developing lung cancer among cancer survivors across 24 different sites of first primary cancer stratified by their LCS eligibility status. Using data from the Patient History Database at the University of Texas MD Anderson Cancer Center, we calculated and compared the cumulative incidence of second primary lung cancer, the overall and the LCS eligibility status-specific, stratified by the site of first primary cancer among cancer survivors. We found that among lung, head and neck (H&N), bladder, cervical, breast, and prostate cancer survivors, the risks of second primary lung cancer were statistically significantly higher compared to the overall risk among all cancer survivors (i.e., all cancer sites combined). Risk ratios (RR) ranged between 1.14 (95%CI:1.00-1.28, p = 0.0431) among prostate cancer survivors to 2.9 (95%CI:2.58-3.26, p < 0.001) among H&N cancer survivors. Other than first primary lung cancer (RR: 1.33; 95%CI:1.14-1.57; p < 0.001), H&N (RR: 1.73; 95%CI:1.45-2.05; p < 0.001) and bladder (RR: 1.32; 95%CI:1-1.74; p = 0.0483) cancer survivors, who were non-eligible for LCS, had significantly higher lung cancer risk than all cancer survivors. In conclusion, H&N, bladder, cervical, breast, and prostate cancer survivors have a high risk of developing second primary lung cancer. Specifically, personal history of H&N and bladder cancer, even among non-eligible for LCS individuals, remain at a sufficiently high risk, which warrants further consideration as an independent eligibility factor for LCS guidelines.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma. 卵巢癌基因检测肿瘤优先工作流程的全国实施和评估。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-16 DOI: 10.1002/ijc.35440

Vera M Witjes, Joanne A de Hullu, Dorien M A Hermkens, Yvonne H C M Smolders, Julie E M Swillens, Sarah-Lotte Slob, Tjalling Bosse, Marian J E Mourits, Margreet G E M Ausems, Marjolijn J L Ligtenberg, Nicoline Hoogerbrugge

{"title":"Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.","authors":"Vera M Witjes, Joanne A de Hullu, Dorien M A Hermkens, Yvonne H C M Smolders, Julie E M Swillens, Sarah-Lotte Slob, Tjalling Bosse, Marian J E Mourits, Margreet G E M Ausems, Marjolijn J L Ligtenberg, Nicoline Hoogerbrugge","doi":"10.1002/ijc.35440","DOIUrl":"https://doi.org/10.1002/ijc.35440","url":null,"abstract":"Despite international agreement on the importance of tumor DNA testing and germline testing for determining PARP inhibitor treatment eligibility in patients with ovarian carcinoma (OC) and for cancer prevention in their relatives, the optimal strategy remains under debate. In the Netherlands, the \"Tumor-First workflow\" was initiated and implemented nationwide: a well-validated tumor DNA test is the primary test for detecting tumor pathogenic variants (PVs) in OC risk genes (BRCA1/2, RAD51C/D, BRIP1, PALB2). The detection of tumor PVs is subsequently used to stratify germline testing and determine treatment eligibility. The Tumor-First workflow is efficient and saves costs. The aim of this study was to evaluate the nationwide implementation of the Tumor-First workflow. We analyzed real-time genetic testing practices, including tumor DNA and germline testing, in patients diagnosed with OC from 2019 to 2023, as identified through the Dutch Pathology Registry (Palga). Testing data were collected from diagnostic pathology and genetic reports. Out of the 3926 OC patients, 2778 (71%) received OC tumor DNA testing as the primary test. Between 2019 and 2023, this percentage increased from 50% to 85%. Of these tumor DNA tests, 2703 (97%) were successful, with 398 (15%) resulting in the identification of a PV in an OC risk gene. Most of these patients (291; 73%) underwent germline testing, and 147 (51%) were found to have a germline PV. We conclude that the nationwide implementation of the Tumor-First workflow for OC was effective. Multidisciplinary efforts contributed to a more efficient detection of germline and somatic PVs in OC risk genes.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular targeted drugs affect the development of antiresorptive-related osteonecrosis of the jaw in patients with lung and kidney cancers. 分子靶向药物影响肺癌和肾癌患者颌骨抗吸收相关骨坏死的发展。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-15 DOI: 10.1002/ijc.35439

Chihiro Kanno, Momoyo Kojima, Yuki Watanabe, Ryosuke Honda, Yu Tezuka, Natsuko Ishida, Tetsuharu Kaneko

{"title":"Molecular targeted drugs affect the development of antiresorptive-related osteonecrosis of the jaw in patients with lung and kidney cancers.","authors":"Chihiro Kanno, Momoyo Kojima, Yuki Watanabe, Ryosuke Honda, Yu Tezuka, Natsuko Ishida, Tetsuharu Kaneko","doi":"10.1002/ijc.35439","DOIUrl":"https://doi.org/10.1002/ijc.35439","url":null,"abstract":"The use of antiresorptive agents in patients with cancer is strongly associated with the development of medication-related osteonecrosis of the jaw, with an incidence of ≥10%. Despite the presence of clinical position papers on this issue, the incidence of medication-related osteonecrosis of the jaw has not decreased. Therefore, we believe there are some unknown underlying factors, so we focused on the use of anticancer agents, especially molecular targeted drugs, in this study. We retrospectively evaluated the data of 366 patients who received antiresorptive agents for metastatic cancer treatment. All patients received proper oral care before antiresorptive agent initiation. Of the 366 patients, 48 (13.1%) developed medication-related osteonecrosis of the jaw. Medication-related osteonecrosis of the jaw developed in 18/55 (32.7%) patients who received molecular targeted drugs and in 30/311 (9.6%) patients who did not (p < 0.001). Among patients with lung cancer, 10/29 (34.5%) patients who received molecular targeted drugs and 5/96 (5.2%) who did not (p < 0.001) developed medication-related osteonecrosis of the jaw. In patients with kidney cancer, medication-related osteonecrosis of the jaw developed in 5/11 patients (45.5%) who received molecular targeted drugs and not in any of the 13 patients who did not (p < 0.01). Molecular targeted drugs significantly affect the development of medication-related osteonecrosis of the jaw. Therefore, in cancer treatment, close attention should be paid to antiresorptive agent use and to the details of anticancer therapies for managing medication-related osteonecrosis of the jaw.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. lenvatinib (L)和eribulin (E)联合治疗晚期实体瘤的II期试验研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-04-15 DOI: 10.1002/ijc.35446

Ranjit Banwait, Heidi Ko, Joel Michalek, Qianqian Liu, Kate Lathrop, Elizabeth Bowhay-Carnes, Georgios Fotopoulos, John Sarantopoulos, Richard Elledge, Josephine Taverna, Anand Karnad, Kalliopi P Siziopikou, Virginia Kaklamani

{"title":"Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.","authors":"Ranjit Banwait, Heidi Ko, Joel Michalek, Qianqian Liu, Kate Lathrop, Elizabeth Bowhay-Carnes, Georgios Fotopoulos, John Sarantopoulos, Richard Elledge, Josephine Taverna, Anand Karnad, Kalliopi P Siziopikou, Virginia Kaklamani","doi":"10.1002/ijc.35446","DOIUrl":"https://doi.org/10.1002/ijc.35446","url":null,"abstract":"This pilot phase II study evaluated the combination of lenvatinib, a multi-kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angiogenesis and resistance mechanisms to anti-angiogenic therapies were primary motivations for combining these agents. The trial enrolled 29 patients, heavily pretreated with at least three prior lines of chemotherapy, and aimed to assess the efficacy and safety of the combination therapy. Overall response rate (ORR) was 24% with the highest responses observed in breast cancer (29%) and lung cancer (33%) patients. Median progression-free survival (PFS) was 7.4 months (95% CI 4.5, NA), and overall survival (OS) was 8.2 months (95% CI 6.4 to 14.9). A significant improvement in both OS and PFS was found in vimentin-negative patients, suggesting that vimentin expression may be a predictor of treatment response. The most common treatment-related adverse events (TRAEs) were oral mucositis, fatigue, neutropenia, and nausea. Grade ≥3 TRAEs included neutropenia (34.5%), febrile neutropenia (17.2%), and hypertension (13.8%), with one fatal case of sepsis reported. While the study demonstrated the potential of lenvatinib and eribulin in advanced solid tumors, particularly breast and lung cancers, it also highlighted the need for further investigation into biomarkers like vimentin to predict therapeutic outcomes. The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0